AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

AtaiBeckley (ATAI) announced today that it will commence a Phase 3 clinical study for its depression treatment candidate, following a constructive meeting with the U.S. Food and Drug Administration (FDA). The company received positive feedback from the FDA regarding its development plan, paving the way for the pivotal trial.